We have located links that may give you full text access.
Uncovering Structure-Activity Relationships of Phenethylamines: Paving the Way for Innovative Mental Health Treatments.
ACS Chemical Neuroscience 2024 Februrary 22
The rapidly evolving psychedelic industry has garnered considerable attention due to 3,4-methylenedioxymethamphetamine-assisted psychotherapy's ground-breaking success in treating moderate-to-severe Post-traumatic Stress Disorder in two Phase 3 clinical trials. This has opened Pandora's box for the development of innovative therapeutic modalities. Of particular interest are the phenethylamines and their ability to inhibit monoamine transporters. In this study, we employed the quantitative structure-activity relationship methodology to develop three vigorous models for the reuptake of serotonin, dopamine, and norepinephrine through monoamine transporters. These models were thoroughly validated using various criteria, including fitting ( R 2 DAT = 0.869, R 2 SERT = 0.828, and R 2 NET = 0.887), internal ( Q 2 looDAT = 0.795, Q 2 looSERT = 0.784, and Q 2 looNET = 0.820), and external (RMSEextDAT = 0.373, R 2 extDAT = 0.831, RMSEextSERT = 0.200, R 2 extSERT = 0.955, RMSEextNET = 0.318, and R 2 extNET = 0.711) criteria.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app